Publications

You can quickly discover relevant content by members of the PHSI-BRG by filtering publications here.

Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): Study protocol for a single-arm, single-stage, phase II trial

BMJ Open 2019; 9(1):e024705

Cole M, Hynes AM, Howel D, Hall L, Abinun M, Allahabadia A, Barrett T, Boelaert K, Drake AJ, Dimitri P, Kirk J, Zammitt N, Pearce S, Cheetham T

DOI

Drooling Reduction Intervention randomised trial (DRI): Comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability

Archives of Disease in Childhood 2018; 103(4):371-376

Parr JR, Todhunter E, Pennington L, Stocken D, Cadwgan J, O’Hare AE, Tuffrey C, Williams J, Cole M, Colver AF

DOI

A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBE trial): Study protocol

Pilot and Feasibility Studies 2016; 2:29

Paleri V, Wood J, Patterson J, Stocken DD, Cole M, Vale L, Franks J, Guerrero-Urbano T, Donnelly R, Barclay S, Rapley T, Rousseau N

DOI

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

Oncotarget 2015; 6(41):43978-43991

Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E

DOI

Abstract 5457: Cytarabine leaves a mutational fingerprint in relapsing leukemia

Cancer Research 2014; 74(Suppl 19):5457

Fordham SE, Cole M, Irving JA, Allan JM

DOI

Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia

Leukemia 2015; 29(2):491-494

Fordham SE, Cole M, Irving JA, Allan JM

DOI

Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team

Journal of Hepatology 2014; 60(1):110-117

Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, Aslam T, Patanwala I, Gaggar S, Cole M, Sumpter K, Stewart S, Rose J, Hudson M, Manas D, Reeves HL

DOI

Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma

Clinical Cancer Research 2013; 19(2):469-479

Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson ADJ, Boddy AV

DOI

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma

Acta Neuropathologica 2012; 123(4):501-513

Ryan SL, Schwalbe EC, Cole M, Lu Y, Lusher ME, Megahed H, O’Toole K, Nicholson SL, Bognar L, Garami M, Hauser P, Korshunov A, Pfister SM, Williamson D, Taylor RE, Ellison DW, Bailey S, Clifford SC

DOI

Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients

Pediatric Blood & Cancer 2011; 57(5):705-897

Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M

DOI

Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy

European Journal of Cancer 2011; 47(10):1556-1563

Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M

DOI

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers

Biochem J 2011; 436(3):671-679

Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ

DOI

TP53 mutations in favorable-risk wnt/wingless-subtype medulloblastomas

Journal of Clinical Oncology 2011; 29(12):e344-e346

Lindsey JC, Hill RM, Megahed H, Lusher ME, Schwalbe EC, Cole M, Hogg TL, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC

DOI

Rapid diagnosis of medulloblastoma molecular subgroups

Clinical Cancer Research 2011; 17(7):1883-1894

Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC

DOI

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival

Pediatric Hematology and Oncology 2011; 28(2):106-114

Bomken S, Davies B, Chong L, Cole M, Wood KM, McDermott M, Tweddle DA

DOI

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

Cancer Chemotherapy and Pharmacology 2010; 66(4):807-812

Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ

DOI

Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose

Pediatric Blood & Cancer 2010; 54(7):983-989

Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson ADJ

DOI

Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate

European Journal of Cancer 2010; 46(10):1841-1847

Israels T, Damen CWN, Cole M, van Geloven N, Boddy AV, Caron HN, Beijnen JH, Molyneux EM, Veal GJ

DOI

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

British Journal of Cancer 2010; 102(6):1003-1009

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV

DOI

High Frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma

Clinical Cancer Research 2010; 16(4):1108–1118

Carr-Wilkinson J, O’Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung N-KV, Boos J, Köhler G, Leuschner I, Pearson ADJ, Lunec J, Tweddle DA

DOI

Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors

European Journal of Cancer 2009; 45(18):3213-3219

Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson ADJ

DOI

Screening infants for neuroblastoma: The parents' perspective

Pediatric Hematology and Oncology 1994; 11(4):433-437

Bell S, Parker L, Cole M, Craft AW

DOI

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

British Journal of Cancer 2009; 101(2):256-262

Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, Curtin NJ

DOI

Human renal function maturation: A quantitative description using weight and postmenstrual age

Pediatric Nephrology 2009; 24(1):67-76

Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NHG

DOI

Estimation of renal function and its potential impact on carboplatin dosing in children with cancer

British Journal of Cancer 2008; 99(6):894-899

Chinnaswamy G, Cole M, Boddy AV, Keir M, Price L, Parry A, English M, Veal GJ

DOI

Mismatch repair defects in childhood acutelymphoblastic leukaemia at diagnosis and relapse

British Journal of Haematology 2008; 141(S1):1-121

Matheson EC, Cole M, Wilkinswand BS, Hall AG

DOI

Pharmacogenetics and metabolism of cyclophosphamidein paediatric cancer patients

Pediatric Blood & Cancer 2007; 49(4):398-605

Chinnaswamv G, Veal GJ, Cole M, Taylor GA, Errington JE, Gerrard M, Boddy AV

DOI

p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma

Cell Cycle 2007; 6(21):2685-2696

Chen L, Malcolm AJ, Wood KM, Cole M, Variend S, Cullinane C, Pearson ADJ, Lunec J, Tweddle DA

DOI

Quantitative assessment of mixed chimerism in allogeneic stem cell transplant patients: A comparison of molecular genetic and cytogenetic approaches

Journal of Pediatric Hematology/Oncology 2007; 29(6):428-431

Routledge D, Jackson A, Bourn D, Bown N, Cole M, Slatter MA, Gennery AR, Curtis A

DOI

Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – A study of the United Kingdom Children's Cancer Study Group

British Journal of Cancer 2007; 96(3):424-431

Veal GJ, Cole M, Errington J, Pearson ADJ, Foot ABM, Whyman G, Boddy AV

DOI

Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?

Pediatric Blood & Cancer 2006; 46(7):723-727

Cole M, Boddy AV, Kearns P, Teh KH, Price L, Parry A, Pearson ADJ, Veal GJ

DOI

A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer

Pediatric Blood & Cancer 2007; 48(7):687-695

Cole M, Price L, Parry A, Picton S, Waters F, Marshall S, Goran C, Parnham A, Wastell H, Reid MM, Pearson ADJ, Boddy AV, Veal GJ

DOI

Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group Study

Clinical Cancer Research 2005; 11(16):5893-5899

Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson ADJ, Howe K, Chisholm JC, Beane C, Brennan B, Waters F, Glaser A, Hemsworth S, McDowell H, Wright Y, Pritchard-Jones K, Pinkerton R, Jenner G, Nicholson J, Elsworth AM, Boddy AV

DOI

Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics

British Journal of Cancer 2004; 90(1):60–64

Cole M, Price L, Parry A, Keir MJ, Pearson ADJ, Boddy AV, Veal GJ

DOI

Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide

British Journal of Clinical Pharmacology 2002; 53(1):83-91

Thomas HD, Porter DJ, Bartelink I, Nobbs JR, Cole M, Elliott S, Newell DR, Calvert AH, Highley M, Boddy AV

DOI

The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system

British Journal of Cancer 2002; 86(7):1117-1123

Burns ASYW, Jaros E, Cole M, Perry R, Pearson AJ, Lunec J

DOI

Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion

Cancer Chemotherapy and Pharmacology 2001; 47(3):222-228

Yule SM, Price L, Cole M, Pearson AD, Boddy AV

DOI

A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia

Medical and Pediatric Oncology 2001; 36(3):365-371

Levett D, Middleton P, Cole M, Reid MM

DOI

Cyclophosphamide metabolism in children with Fanconi's anaemia

Bone Marrow Transplantation 1999; 24(2):123-128

Yule SM, Price L, Cole M, Pearson AD, Boddy AV

DOI

The effect of fluconazole on cyclophosphamide metabolism in children

Drug Metabolism and Disposition 1999; 27(3):417-421

Yule SM, Walker D, Cole M, McSorley L, Cholerton S, Daly AK, Pearson ADJ, Boddy AV

A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children

British Journal of Cancer 1998; 77(12):2318-2323

Lowis SP, Price L, Pearson AD, Newell DR, Cole M

DOI

Neonatal vitamin K administration and childhood cancer in the north of England: Retrospective case-control study

BMJ 1998; 316(7126):189-193

Parker L, Cole M, Craft AW, Hey EN

DOI

Cyclophosphamide pharmacokinetics in children

British Journal of Clinical Pharmacology 1996; 41(1):13-19

Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson ADJ, Idle JR

DOI

Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients

European Journal of Cancer 1995; 31(11):1804-1810

Peng B, Boddy AV, Cole M, Pearson ADJ, Chatelut E, Rubie H, Newell DR

DOI

Urinary creatinine adjusted reference ranges for homovanillic and vanillylmandelic acid in children and adults

Clinica Chimica Acta 1995; 236(1):19-32

Cole M, Craft AW, Parker L, Bell S, Seviour JA, McGill AC, Dale G

DOI

Screening for wilms' tumour in patients with aniridia, Beckwith syndrome, or hemihypertrophy

Medical and Pediatric Oncology 1995; 224(4):231-234

Craft AW, Parker L, Stiller C, Cole M

DOI

The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion

Cancer Chemotherapy and Pharmacology 1995; 36(1):53-60

Boddy AV, Cole M, Pearson AD, Idle JR

DOI

Expression of µ Class Glutathione S-Transferase Correlates with Event-free Survival in Childhood Acute Lymphoblastic Leukemia

Cancer Research 1994; 54(20):5251-5254

Hall AG, Autzen P, Cattan AR, Malcolm AJ, Cole M, Kernahan J, Reid MM

Screening infants for neuroblastoma: The parents' perspective in false-positive cases

Pediatric Hematology and Oncology 1994; 11(2):157-163

Bell S, Parker L, Cole M, Craft AW

DOI

Inaccuracy of glomerular filtration rate estimation from height/plasma creatinine ratio

Archives of Disease in Childhood 1994; 70(5):387-390

Skinner R, Cole M, Pearson AD, Keir MJ, Price L, Wyllie RA, Coulthard MG, Craft AW

DOI

False positive results in a neuroblastoma screening programme

Medical and Pediatric Oncology 1994; 22(3):181-186

Bell S, Parker L, Craft AW, Dale G, McGill AC, Seviour J, Cole M, Smith J

DOI

Etoposide pharmacokinetics in children: The development and prospective validation of a dosing equation

Cancer Res 1993; 53(20):4881-4889

Lowis SP, Pearson ADJ, Newell DR, Cole M

Creatinine related reference ranges for urinary homovanillic acid and vanillylmandelic acid at 6 months of age

Archives of Disease in Childhood 1993; 68(3):376–378

Cole M, Parker L, Craft AW, Bell S, Dale G, McGill AC, Seviour JA, Smith J

DOI

Screening for neuroblastoma in the north of England

BMJ 1992; 3055(6864):1260-1263

Parker L, Craft AW, Dale G, Bell S, Cole M, McGill AC, Seviour JA, Smith J

DOI

A pilot study of screening for neuroblastoma in the north of England

Journal of Pediatric Hematology/Oncology 1992; 14(4):337-341

Craft AW, Parker L, Dale G, McGill AC, Seviour JA, Bell S, Cole M, Smith J

Mike Cole

Biostatistician

Contact

Publications